Serum IL-33 but not ST2 level is elevated in intermittent allergic rhinitis and is a marker of the disease severity

Inflammation Research

Volumn 61, Issue 6, 2012, Pages 547-550

  Glück, Joanna ^a   Rymarczyk, Barbara ^a   Rogala, Barbara ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Bronchial asthma; IgE; IL 33; Intermittent allergic rhinitis; ST2; Total nasal symptom score

Indexed keywords

DECONGESTIVE AGENT; IMMUNOGLOBULIN E; INTERLEUKIN 33; MEMBRANE PROTEIN; PROTEIN ST2; STEROID; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; NASAL PRURITUS; NOSE CONGESTION; PRICK TEST; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHINORRHEA; SNEEZING;

ADULT; ALLERGENS; FEMALE; HUMANS; IMMUNOGLOBULIN E; INTERLEUKINS; MALE; MIDDLE AGED; POACEAE; POLLEN; RECEPTORS, CELL SURFACE; RHINITIS, ALLERGIC, SEASONAL; SEVERITY OF ILLNESS INDEX; TREES; YOUNG ADULT;

EID: 84865149660     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0443-9     Document Type: Article

References (26)

1. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779-86. (Pubitemid 47578297)
2. Cl Hsu, Neilsen CV, Bryce PJ. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One. 2010; 3(5):e11944.
3. Moulin D, et al. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine. 2007;40: 216-25. (Pubitemid 350213434)
4. Ho LH, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-Fc epsilon RI signals. J Leukoc Biol. 2007;82:1481-90. (Pubitemid 350276960)
5. Iikura M, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87:971-8. (Pubitemid 47429189)
6. Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA. 1998;95:6930-5. (Pubitemid 28278084)
7. Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med. 1998;187:787-94. (Pubitemid 28115194)
8. Lecart S, Lecointe N, Subramaniam A, et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol. 2002;32:2979-87. (Pubitemid 35238191)
9. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277-81. (Pubitemid 34001295)
10. Ali M, Zhang G, Thomas WR, et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens. 2009;73: 206-12.
11. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007;282:26369-80. (Pubitemid 47443815)
12. Shimizu M, Matsuda A, Yanagisawa K, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet. 2005;14:2919-27. (Pubitemid 41418796)
13. Savenije OE, Kerkhof M, Reijmerink NE, et al. Interleukin-1 receptor-like 1 polymorphisms are associated with serum IL1RL1-a, eosinophils, and asthma in childhood. J Allergy Clin Immunol. 2011;127:750-6. e1-5.
14. Pushparaj PN, Tay HK, H'ng SC, et al. The cytokine interleukin- 33 mediates anaphylactic shock. Proc Natl Acad Sci USA. 2009;106:9773-8.
15. Lloyd CM. IL-33 family members and asthma-bridging innate and adaptative immune response. Curr Opin Immunol. 2010;22: 800-6.
16. Prefontaine D, Nadigel J, Chouciali F, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol. 2010;125:752-4.
17. Sakashita M, Yoshimoto T, Hirota T, et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy. 2008;38:1875-81.
18. Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008. Allergy. 2008;63:8-160.
19. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2010. Available from: http://www.ginasthma.org/.
20. Dreborg S, Frew A. Position papers: allergen standardization and skin tests. Allergy. 1993;48:9-82.
21. Miller A. Role of IL-33 in inflammation and disease. J Inflamm. 2011;8:22-33.
22. Miller AM, Asquith DL, Hueber AJ, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res. 2010;107:650-8.
23. Matsuba-Kitamura S, Yoshimoto T, Yasudal K, et al. Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol. 2010;22:479-89.
24. Kim YH, Yang TY, Park C-S, et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy. 2012;67:183-90. doi:10.1111/j.1398-9995.2011.02735.x.
25. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev. 2011;242:10-30.
26. Kurokawa M, Matsukura S, Kawaguchi M, et al. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol. 2011;155(Suppl 1):12-20.